clinical trial · NCT07227922
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Moderate Renal Impairment12mg clofutriben
brief summary
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
started
Nov 30, 2025
primary completion
Apr 30, 2026
completion
Jul 1, 2026
last updated
Dec 23, 2025
detailed description
Following Screening, enrolled participants will be confined to a clinical research unit for 6 days. Each participant will receive a single oral dose of clofutriben. Clofutriben PK, safety, and tolerability will be assessed. The participants will be contacted by telephone 4 weeks after clofutriben administration for safety follow-up.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol